Moderate amplifications of the c-myc gene correlate with molecular and clinicopathological parameters in colorectal cancer
1998

C-myc Gene Amplification in Colorectal Cancer

Sample size: 70 publication Evidence: moderate

Author Information

Author(s): L Masramon, R Arribas, S T6rtola, M Perucho, MA Peinado

Primary Institution: Institut de Recerca Oncologica, Hospital Duran i Reynals

Hypothesis

Is there a relationship between c-myc gene amplification and molecular and clinicopathological variables in colorectal carcinomas?

Conclusion

C-myc gene amplification occurs in about 26% of colorectal cancer cases and is associated with more advanced tumor stages and mutations in the p53 gene.

Supporting Evidence

  • C-myc amplification was found in 26% of colorectal cancer cases analyzed.
  • The incidence of c-myc amplification was higher in advanced Dukes' stages.
  • C-myc amplification was associated with mutations in the p53 tumor-suppressor gene.

Takeaway

This study found that a gene called c-myc is often more active in colorectal cancer, especially in more serious cases.

Methodology

The study used a DNA fingerprinting method called targeted arbitrarily primed PCR (TAP-PCR) to analyze c-myc gene amplification in colorectal carcinoma samples.

Limitations

The study's findings may be affected by the presence of non-tumor cells in the samples, which could mask the true degree of amplification.

Statistical Information

P-Value

0.048

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication